



NDA 21-758/S-002

Medicis Pharmaceutical Corp.
R. Todd Plott M.D.
Vice President, Clinical Research and Regulatory Affairs
8125 N. Hayden Road
Scottsdale, AZ 85258

Dear Dr. Plott:

Please refer to your supplemental new drug application dated May 26, 2005 received May 27, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Vanos (fluocinonide) Cream, 0.1%.

We also acknowledge receipt of your communication dated November 21, 2005, amending the supplemental application.

This CBE-0 supplemental application provides for modification of the analytical test method (b) (4)
(b) (4) (b) (4)

We have completed our review of this supplemental new drug application, and it is approved as of the date of this letter.

We remind you that you must comply with the reporting requirements for an approved NDA (21CFR 314.80 and 314.81).

If you have any questions, call Melinda Harris-Bauerlien, Regulatory Project Manager, at (301) 796-2110.

Sincerely,

{See appended electronic signature page}

Moo-Jhong Rhee, Ph.D.
Chief, Branch III
Division of Pre-Marketing Assessment II
Office of New Drug Quality Assessment
Office of Pharmaceutical Science
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Moo-Jhong Rhee
11/23/2005 02:13:29 PM